PSY18 HEALTH CARE COSTS AND MEDICATION COMPLIANCE AMONG ELDERLY FIBROMYALGIA PATIENTS ON DULOXETINE VERSUS PREGABALIN  by Sun, P et al.
A208 Abstracts
payer. METHODS: A retrospective study using double source of information both 
registration of authorized services and consumption of the insurer’s database as the 
histories of two institutions specialized pain care belonging to network service pro-
viders the same insurer, using a random sample of patients (n = 271) within a 
universe of 803 patients between 2002 and 2008. Using Bottom-up methodology is 
performed a micro-costing analysis grouping by frequency setting monthly consump-
tion and annual costs with measures of central tendency and dispersion, costs were 
estimated at constant prices of 2008. RESULTS: The average age of presentation 
of the diseases was 37 years, there were no signiﬁcant differences in gender distribu-
tion. (47.6% men and 52.4% women) The average total annual cost per patient 
was US$ 3322, the trend of the data series showed an increase of total costs in the 
period 2002–2006 and then a reduction in the period 2006–2008 with variable 
behavior depending on the category costs. The services represent a greater ﬁnancial 
burden are the outpatient medicines (35%) and osteosynthesis materials (30%). We 
estimated the annual expected frequency of use for a patient with these characteristics. 
It is possible that cost trends are explained by the incorporation of a pain manage-
ment program of the insurer with the use of new medicines that improve the clinical 
picture of patients. CONCLUSIONS: Chronic pain and neuropathic pain represent 
a signiﬁcant economic burden, is essential to identify the most cost effective interven-
tions in their management.
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OBJECTIVES: Obesity was associated with increasing morbidity and mortality of 
many chronic diseases, such as cardiovascular diseases, hypertension, diabetes melli-
tus, and stroke. Furthermore, the obese subjects had higher medical utilization with 
increasing BMI status, especially for the outpatient visits. The purpose of this study 
is to evaluate medical service utilization and medical expenditure associated with the 
obesity-related diseases in different weight status subjects in Taiwan. METHODS: A 
cross-sectional survey based on the National Health Interview Survey (NHIS) was 
conducted in 2001. Subjects greater than 20 years old who lived in Taiwan, correlated 
by National Health Insurance (NHI) during 2001–2004 were included and ﬁnally 
12,283 subjects were used for analyses. RESULTS: In general, male subjects were 
older, taller, heavier, larger BMI, higher medical utilization usage and expenditure 
than female. The higher BMI status, the higher prevalence of hypertension, type 2 
diabetes, cardiovascular diseases and gout. All obesity-related disorders had increasing 
trends with larger BMI (p < 0.001). Obese subjects (BMI ≥a 27 kg/m2) had the highest 
prevalence of hypertension (32.8%), following by Type 2 diabetes (25.6%). After 
adjusting for age, smoking, drinking and obesity-related disorders, the higher the BMI, 
the use of medical utilization in out-patient from 1.33 to 4.04 visit/year (p < 0.05) 
and in-hospital from 0.05 to 0.07 admission/year (p < 0.05). The average out-patient 
expenditure (all cost including physician-fee and drug cost) per year was NT$ 1201, 
1857, 3960 and 5118 dollars (exchange rate as 1USD = 32NTD) for underweight, 
normal, overweight and obesity subjects. CONCLUSIONS: In this study, the higher 
BMI status, the more medical utilization and higher out-patient medical expenditure 
was found. These results may help us to make decision on policy for resources alloca-
tion and strategies priority of obesity to resolve the major public health problem even 
in the developing country such as Taiwan.
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OBJECTIVES: Patients with β-thalassemia, sickle cell disease (SCD), and myelodys-
plastic syndromes (MDS) require chronic blood transfusions, which lead to iron 
overload and substantial morbidity (e.g., cardiac failure, diabetes, hypothyroidism, 
hypogonadism) and mortality. To reduce the excess iron and its deleterious effects, 
available iron chelation therapy (ICT) in the US includes oral deferasirox or infusional 
deferoxamine (DFO). The aim of this literature review was to assess the economic 
burden of iron overload among US patients with β-thalassemia, SCD, and MDS. 
METHODS: We identiﬁed economic evaluations of iron overload in patients with 
β-thalassemia, SCD and MDS that either were published in MEDLINE-indexed, 
English-language journals since 1999, or appeared in professional society websites and 
scientiﬁc meeting abstracts. We summarized and critically compared costs (adjusted 
to 2009 USD) from this literature. RESULTS: The majority of studies assessed direct 
medical costs associated with iron overload among patients with β-thalassemia and 
SCD, where the association was reported as costs of ICT with DFO. Annual costs of 
patients with complications (notably cardiac disease, diabetes, etc.) varied from 
$72,000 to $103,000 per patient. Annual direct medical costs of patients undergoing 
ICT varied by disease—$47,000 and $74,000 per patient for β-thalassemia and SCD, 
respectively. Less information was available for MDS patients. ICT accounted for 
~33% of total medical costs, followed by costs for inpatient and outpatient care. Little 
information was available on costs incurred by untreated patients or those non-
compliant with their ICT. CONCLUSIONS: The economic burden of iron overload 
among transfusion dependent patients with β-thalassemia, SCD, and MDS in the US 
is substantial. The majority of information is on SCD and β-thalassemia, while the 
economic burden of iron overload in MDS is not clearly elucidated. More information 
is needed on the differential real-world impact of ICT choices on treatment adherence 
and on the economic burden overall.
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OBJECTIVES: To examine whether duloxetine initiators had different medication 
compliance or health care costs than pregabalin initiators among elderly patients with 
ﬁbromyalgia. METHODS: A large, US national claims database was analyzed to 
identify ﬁbromyalgia patients aged 65 and above with Medicare supplemental insur-
ance who initiated duloxetine or pregabalin in 2006. Initiation was deﬁned as no pill 
coverage in the previous 90 days, with the ﬁrst initiation date as the index date. All 
selected patients had 12-month continuous enrollment before and after the index date. 
Duloxetine initiators with diabetic peripheral neuropathic pain (DPNP) or depression, 
and pregabalin initiators with DPNP, post-herpetic neuralgia or epilepsy diagnosis in 
the 12-month pre-index period were excluded. Propensity scoring was applied to 
construct the duloxetine and pregabalin cohorts controlling for differences in demo-
graphics, pre-index clinical and economic characteristics, and pre-index treatment 
patterns. Medication compliance (i.e., medication possession ratio (MPR), proportion 
of patients with MPR ≥ 80%), and health care costs over the ﬁrst 12-month post-index 
period were examined between cohorts. RESULTS: Patients in the duloxetine (n = 
614) and pregabalin (n = 1188) cohorts had a mean age of 75 years. The most common 
comorbid conditions in both cohorts were cardiovascular disease (88.1% vs. 85.8%), 
neuropathic pain other than DPNP (72.5% vs. 72.2%), low back pain (71.6% vs. 
71.3%), and osteoarthritis (57.4% vs. 57.5%), while opioids (83.3% vs. 83.0%) were 
the most commonly prescribed medication over the 12 months pre-index period. 
Adjusting for demographics, pre-index clinical and economic characteristics, and prior 
medication history, duloxetine initiators had signiﬁcantly higher MPR (0.70 vs. 0.56, 
p < 0.05), higher proportion of patients with MPR ≥ 0.8 (44.8% vs. 29.0%, p < 0.05), 
and signiﬁcantly lower total health care costs ($26,323 vs. $27,112, p < 0.05) over 
the 12-month post-index period than pregabalin patients. CONCLUSIONS: Among 
elderly ﬁbromyalgia patients, duloxetine initiators had better medication compliance 
and lower direct health care costs than pregabalin initiators.
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OBJECTIVES: This study compared number of patient visits and out-of-pocket costs 
for multiple myeloma (MM) patients treated with bortezomib (BOR; Velcade®; IV 
administration), lenalidomide (LEN; Revlimid®; oral), thalidomide (THAL; Thalo-
mid®; oral), or other unspeciﬁed chemotherapies/radiation therapy. METHODS: 
Patients aged > = 18 yrs, diagnosed with MM between January 1, 2005 and September 
30, 2007, and treated with BOR, LEN, THAL, or other unspeciﬁed chemotherapies/
radiation therapy were identiﬁed using claims data from a large US commercial health 
plan (~14 million members). Treatment episodes (each course of therapy) were identi-
ﬁed from patient records. Health-care utilization (number of ambulatory patient visits) 
and inﬂation-adjusted patient out-of-pocket costs, including co-pays and deductibles, 
were examined for 1 yr from the beginning of each treatment episode. Multivariate 
regression analyses were performed to control for patient characteristics, comorbidi-
ties, and line of treatment. RESULTS: A total of 2642 treatment episodes for 1900 
patients were identiﬁed. Most episodes were “other chemotherapy/radiation therapy” 
(n = 1759), followed by THAL (n = 549), BOR (n = 244) and LEN (n = 90). There 
were no between-group differences in inpatient or emergency room visits. Patients 
treated with BOR appeared to have more ambulatory visits compared with patients 
treated with LEN (77 versus 61; p < 0.05); however, this difference was not signiﬁcant 
after multivariate analysis (66 versus 57; p > 0.05). The total adjusted patient out-of-
pocket costs were signiﬁcantly less for patients treated with BOR ($3504) than for 
those treated with THAL ($4443, p < 0.05) or LEN ($4766, p < 0.05). These differ-
ences were greatest for Medicare patients, with the adjusted patient costs of THAL 
($8,824) and LEN ($12,568) respectively, nearly 2 and 3 times greater than the 
adjusted costs of BOR ($4,395). CONCLUSIONS: There was no signiﬁcant advantage 
in terms of fewer patient visits with the oral drugs (THAL, LEN) over BOR. Direct 
out-of-pocket costs were signiﬁcantly higher for patients treated with THAL and LEN 
compared with BOR, especially for Medicare patients.
